Tumor Regression Grade Predicts Survival in Locally Advanced Gastric Adenocarcinoma Patients with Lymph Node Metastasis

Table 2

Univariate analysis of clinicopathological factors.

Prognostic factors	OS		DFS
	Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value
Gender	1.298 (0.896, 1.882)	0.168	1.218 (0.854, 1.737)	0.276
Age	1.572 (1.084, 2.260)	0.017	1.445 (1.013, 2.062)	0.042
Tumor location		0.001		0.001
L	1		1
M	0.727 (0.443, 1.191)	0.206	0.683 (0.424, 1.102)	0.118
U	1.098 (0.620, 1.945)	0.748	0.921 (0.523, 1.621)	0.776
GEJ	2.262 (1.041, 4.915)	0.039	2.251 (1.089, 4.653)	0.028
Diffuse	2.537 (1.511, 4.259)	0.001	2.636 (1.612, 4.309)	0.001
Tumor size (cm)	2.647 (1.784, 3.928)	0.001	2.198 (1.535, 3.148)	0.001
ypT		0.001		0.001
0	1		1
1-2	1.968 (0.252, 15.379)	0.519	2.463 (0.322, 18.829)	0.385
3-4	8.166 (1.140, 58.501)	0.001	8.953 (1.251, 64.084)	0.029
ypN		0.001		0.001
0	1		1
1	5.398 (2.860, 10.187)	0.001	3.338 (1.868, 5.966)	0.001
2	5.284 (2.873, 9.718)	0.001	4.291 (2.570, 7.165)	0.001
3	13.507 (7.383, 24.711)	0.001	9.483 (5.662, 15.884)	0.001
ypTNM
I-II vs. III	9.214 (1.161, 73.009)	0.036	4.480 (3.005, 6.678)	0.001
Histological type	1.576 (1.117, 2.222)	0.010	1.471 (1.060, 2.041)	0.021
Lauren classification	2.223 (1.557, 3.174)	0.001	2.136 (1.528, 2.987)	0.001
Grade of differentiation	3.521 (2.023, 6.129)	0.001	3.315 (1.999, 5.498)	0.001
Vascular or lymphatic invasion	2.242 (1.568, 3.204)	0.001	2.133 (1.513, 3.005)	0.001
Nervous invasion	1.652 (1.142, 2.390)	0.008	1.610 (1.131, 2.291)	0.008
Mandard TRG
1-2 vs. 3-5	3.822 (2.371, 6.162)	0.001	3.374 (2.190, 5.200)	0.001
Neoadjuvant therapy		0.344		0.627
FOLFOX	1		1
SOX	0.895 (0.594, 1.350)	0.597	0.855 (0.576, 1.269)	0.436
XELOX	0.520 (0.216, 1.250)	0.144	0.728 (0.347, 1.526)	0.400
Adjuvant treatment	1.659 (0.996, 2.763)	0.052	1.790 (1.117, 2.871)	0.016